Table 4 from TAPISTRY: A Phase II Study of Atezolizumab in Patients with Tumor Mutational Burden–High Tumors
收藏NIAID Data Ecosystem2026-05-10 收录
数据链接：
官方服务：
资源简介：
ORR, DOR, and PFS by IRC in patients with TMB ≥13 mut/Mb and TPS and CPS <1% and ≥1%.
创建时间：
2026-03-16
